Sequenom, Inc.
 (SQNM)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Jul. 24, 2013, 5:53 PM
    After-hours top gainers, as of 5:15 p.m.: FB +19%. TRIP +15%. BIDU +13%. XOOM +12%. TQNT +11%.
    After-hours top losers: SQNM -33%. CROX -21%. EQIX -8%. RT -7%. VAR -6%.
    | Jul. 24, 2013, 5:53 PM | 2 Comments
  • Jul. 24, 2013, 4:25 PM

    More on Sequenom's (SQNM) Q2: CMM diagnostics services revenues come in at $24.5M. The company says it (as well as competitors) "experienced delays in receipt of payments as a result of molecular diagnostics coding changes adopted by CMS, Medicaid and third party payors." Total tests accessioned rise 130% to 46,700 patient samples (38K MaterniT21 PLUS samples). Overall gross margin climbs 200 bps Y/Y. CFO Paul Maier says he is "disappointed by the delay in the collection of diagnostic segment revenues during the second quarter," but notes that collections should improve in H2. Update 4:39: Shares slide 25% AH. (PR)

    | Jul. 24, 2013, 4:25 PM
  • Jul. 24, 2013, 4:12 PM
    Sequenom (SQNM): Q2 EPS of -$0.27 misses by $0.06. Revenue of $34.9M misses by $11.35M. (PR)
    | Jul. 24, 2013, 4:12 PM
  • Jun. 12, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: SWY +30%. SPRD +25%. PVH +7%. PSMI +6%. SVU +6%.
    After-hours top losers: SIGM -8%. QCOR -7%. SQNM -5%. ECYT -3%. VLCCF -3%.
    | Jun. 12, 2013, 5:30 PM | 3 Comments
  • Jun. 7, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: EQIS +6%. GFA +5%. VWO +4%. DLR +3%. HILL +2%.
    After-hours top losers: MIND -16%. UAL -7%. SQNM -4%. PBI -3%. ADBE -3%.
    | Jun. 7, 2013, 5:30 PM
  • May 31, 2013, 11:38 AM

    Jefferies assumes Sequenom (SQNM +0.7%) at Buy (price target $6) citing momentum for the company's MaterniT21 test which analyst Brandon Couillard says is "ramp[ing] at a blistering clip." (Related: Credit Suisse sees robust test volumes)

    | May 31, 2013, 11:38 AM
  • May 30, 2013, 4:14 PM

    Sequenom (SQNM +1.7%) finishes higher after saying it's entered into a technology licensing and marketing agreement with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. Under the agreement, SQNM will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France, as well as Belgium, Luxembourg and portions of the Middle East and Africa. The contract is effective immediately and active through 2018.

    | May 30, 2013, 4:14 PM
  • May 13, 2013, 11:53 AM

    Credit Suisse upgrades Sequenom (SQNM +7.5%) to Neutral and raises its price target to $4.50 from $4, citing decreased risk stemming from the company's five-year agreement with Blue Cross and Blue Shield (see CC) for the MaterniT21 PLUS test. Analyst Vamil Divan notes that "following daily moves in [the stock] can get one dizzy" — today is no exception — but CS sees SQNM running 175K tests in FY13 versus company projections of 150K and says that ultimately, robust volumes are enough to support the story at least for the foreseeable future. (See also: Q1 earnings)

    | May 13, 2013, 11:53 AM
  • May 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | May 10, 2013, 12:52 PM
  • May 10, 2013, 9:10 AM
    Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
    Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%.
    | May 10, 2013, 9:10 AM
  • May 9, 2013, 5:51 PM

    More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue estimates. Total sales jumped 158% over the prior year, led by continued growth in diagnostic sales. Total cost of revenues increased, primarily due to the significant increase in its test volumes and costs to support increased testing capacity. Shares +5% AH.

    | May 9, 2013, 5:51 PM
  • May 9, 2013, 4:14 PM
    Sequenom (SQNM): Q1 EPS loss of -$0.26 misses by $0.02. Revenue of $38.5M (+158% Y/Y) in line. (PR).
    | May 9, 2013, 4:14 PM
  • May 9, 2013, 12:10 AM

    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX

    | May 9, 2013, 12:10 AM
  • May 8, 2013, 5:35 PM

    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX

    | May 8, 2013, 5:35 PM
  • Apr. 4, 2013, 8:39 AM

    Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about proposed regulation of prenatal screening tests likely overstates the case as the FDA "has missed its window to regulate the non-invasive prenatal testing market." Analyst Zarak Khurshid upgrades the stock to Outperform from Neutral and reiterates a price target of $5. Shares +3.4% premarket. 

    | Apr. 4, 2013, 8:39 AM
  • Mar. 7, 2013, 4:16 PM
    Sequenom (SQNM): Q4 EPS of -$0.29 misses by $0.07. Revenue of $33.7M (+117% Y/Y) beats by $1.68M. Shares -2% AH. (PR)
    | Mar. 7, 2013, 4:16 PM
Company Description
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.
Sector: Healthcare
Industry: Biotechnology
Country: United States